ATLANTA, GA – – (Globe Newswire – April 18, 2023) – – Holzer & Holzer, LLC is investigating whether Alvotech (“Alvotech” or the “Company”) (NASDAQ: ALVO) complied with federal securities laws.  On April 13, 2023, Alvotech disclosed that the FDA “issued a complete response letter (“CRL”) for Alvotech’s Biologics License Application” which noted certain deficiencies and stated that the FDA requires the deficiencies to be “satisfactorily resolved before the application can be approved.” Following this news, the price of the Company’s stock dropped.

If you purchased Alvotech  stock and suffered a loss on that investment, you are encouraged to contact Corey Holzer, Esq. at  or Joshua Karr, Esq. at, call our toll-free number at (888) 508-6832, or visit our website at to discuss your legal rights.


Registration Deadline

Lead Plaintiff Deadline Has Passed

Submit Your Information

Shares Purchased(Required)
Date of Shares Purchased
Number of Shares Acquired
Acquisition Price Per Share
Shares Sold
Date of Shares Sold
Number of Shares Sold
Selling Price Per Share